Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HSP90AB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HSP90AB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HSP90AB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HSP90AB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HSP90AB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HSP90AB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HSP90AB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HSP90AB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HSP90AB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HSP90AB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HSP90AB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
GO:190336210 | Cervix | CC | regulation of cellular protein catabolic process | 72/2311 | 255/18723 | 5.98e-12 | 2.10e-09 | 72 |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:190305010 | Cervix | CC | regulation of proteolysis involved in cellular protein catabolic process | 60/2311 | 221/18723 | 1.82e-09 | 1.98e-07 | 60 |
GO:004440310 | Cervix | CC | biological process involved in symbiotic interaction | 71/2311 | 290/18723 | 7.94e-09 | 6.98e-07 | 71 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:200005810 | Cervix | CC | regulation of ubiquitin-dependent protein catabolic process | 47/2311 | 164/18723 | 1.63e-08 | 1.25e-06 | 47 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00300108 | Cervix | CC | establishment of cell polarity | 42/2311 | 143/18723 | 4.30e-08 | 2.62e-06 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0461244 | Oral cavity | EOLP | Antigen processing and presentation | 29/1218 | 78/8465 | 4.69e-07 | 4.78e-06 | 2.82e-06 | 29 |
hsa0541846 | Oral cavity | EOLP | Fluid shear stress and atherosclerosis | 41/1218 | 139/8465 | 2.95e-06 | 2.16e-05 | 1.28e-05 | 41 |
hsa0521524 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa0415123 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa0414155 | Oral cavity | EOLP | Protein processing in endoplasmic reticulum | 70/1218 | 174/8465 | 2.84e-17 | 3.06e-15 | 1.81e-15 | 70 |
hsa0541756 | Oral cavity | EOLP | Lipid and atherosclerosis | 62/1218 | 215/8465 | 2.28e-08 | 2.83e-07 | 1.67e-07 | 62 |
hsa0461254 | Oral cavity | EOLP | Antigen processing and presentation | 29/1218 | 78/8465 | 4.69e-07 | 4.78e-06 | 2.82e-06 | 29 |
hsa0541856 | Oral cavity | EOLP | Fluid shear stress and atherosclerosis | 41/1218 | 139/8465 | 2.95e-06 | 2.16e-05 | 1.28e-05 | 41 |
hsa0521534 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa0415133 | Oral cavity | EOLP | PI3K-Akt signaling pathway | 73/1218 | 354/8465 | 7.03e-04 | 2.69e-03 | 1.59e-03 | 73 |
hsa0513263 | Oral cavity | NEOLP | Salmonella infection | 67/1112 | 249/8465 | 3.05e-09 | 7.46e-08 | 4.69e-08 | 67 |
hsa0414162 | Oral cavity | NEOLP | Protein processing in endoplasmic reticulum | 49/1112 | 174/8465 | 9.02e-08 | 1.37e-06 | 8.59e-07 | 49 |
hsa0541863 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0415141 | Oral cavity | NEOLP | PI3K-Akt signaling pathway | 79/1112 | 354/8465 | 8.42e-07 | 9.92e-06 | 6.24e-06 | 79 |
hsa0521542 | Oral cavity | NEOLP | Prostate cancer | 28/1112 | 97/8465 | 3.15e-05 | 2.57e-04 | 1.62e-04 | 28 |
hsa0541763 | Oral cavity | NEOLP | Lipid and atherosclerosis | 47/1112 | 215/8465 | 2.39e-04 | 1.61e-03 | 1.01e-03 | 47 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa0461261 | Oral cavity | NEOLP | Antigen processing and presentation | 20/1112 | 78/8465 | 2.09e-03 | 9.00e-03 | 5.66e-03 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSP90AB1 | SNV | Missense_Mutation | | c.1994C>G | p.Ser665Cys | p.S665C | P08238 | protein_coding | deleterious(0.03) | benign(0.078) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HSP90AB1 | SNV | Missense_Mutation | rs756933263 | c.1655N>T | p.Lys552Met | p.K552M | P08238 | protein_coding | deleterious(0.01) | probably_damaging(0.951) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HSP90AB1 | SNV | Missense_Mutation | | c.1367N>T | p.Arg456Leu | p.R456L | P08238 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-E2-A1IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
HSP90AB1 | SNV | Missense_Mutation | novel | c.748N>G | p.Ile250Val | p.I250V | P08238 | protein_coding | tolerated(0.42) | benign(0) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | deletion | Frame_Shift_Del | novel | c.217_233delATTGACATCATCCCCAA | p.Ile73ProfsTer19 | p.I73Pfs*19 | P08238 | protein_coding | | | TCGA-A8-A08O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | PD |
HSP90AB1 | SNV | Missense_Mutation | rs770945397 | c.1346G>A | p.Arg449His | p.R449H | P08238 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSP90AB1 | SNV | Missense_Mutation | | c.87N>G | p.Ile29Met | p.I29M | P08238 | protein_coding | deleterious(0.01) | possibly_damaging(0.863) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | SNV | Missense_Mutation | | c.52N>G | p.Gln18Glu | p.Q18E | P08238 | protein_coding | deleterious(0.02) | possibly_damaging(0.48) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSP90AB1 | SNV | Missense_Mutation | | c.52N>G | p.Gln18Glu | p.Q18E | P08238 | protein_coding | deleterious(0.02) | possibly_damaging(0.48) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HSP90AB1 | SNV | Missense_Mutation | rs370988754 | c.502C>T | p.Arg168Cys | p.R168C | P08238 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | ZERANOL | ZERANOL | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | ZEARALENONE | ZEARALENONE | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | RADANAMYCIN | RADANAMYCIN | 16464590 |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | GAMBOGIC ACID | GAMBOGIC ACID | 21486005 |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | AUY922 | | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | RHEIN | RHEIN | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | inhibitor | 354702300 | GELDANAMYCIN | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | IPI-504 | RETASPIMYCIN HYDROCHLORIDE | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | MPC-3100 | | |
3326 | HSP90AB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TUMOR SUPPRESSOR | | CELASTROL | CELASTROL | 25756299,21129982 |